About Us
About Us
  • Board Of Directors
  • Collaborators
  • Staff Directory
  • Job Openings
Our Legacy
Our Legacy
  • Achievements
  • History
  • Irene Diamond
  • Photo Gallery
Current Research
Current Research
  • Our Scientists and Labs
    • Paul Bieniasz
    • Cecilia Cheng-Mayer
    • Robert Gifford
    • Theodora Hatziioannou
    • David D. Ho
    • Yaoxing Huang
    • Martin Markowitz
    • Moriya Tsuji
  • Our Scientists and Labs
    • Mario Chin
    • Masahiro Yamashita
  • Core Facilities
    • Personnel
    • Flow Cytometry
    • Microscope Imaging Facility
Clinical Trials
Clinical Trials
  • HIV+
    • Newly Infected With HIV
    • Living With HIV
    • Physicians
    • FAQ's
  • HIV.
    • Healthy Volunteer
    • FAQ's
Focus On HIV
Focus On HIV
  • Facts About HIV and AIDS
  • HIV Biology
    • The HIV Virus Particle
    • The HIV Replication Cycle
Giving Center
Giving Center
  • Online Giving
  • Other Giving Opportunities
  • Financial Summary
News Center
News Center
  • ADARC In The News
  • Seminars
  • Newsletters and Brochures
  • For Journalists
China Aids Initiative
China Aids Initiative
Multimedia Library
Multimedia Library
Talks at ADARC
Talks at ADARC
ADARC Gala
ADARC Gala
  • Gala video
  • Gala photo
  • leadership committee
  • Online Giving
Register for Updates
Register for Updates
Current Research

Scientific Overview


Cecilia Cheng-Mayer
CHOOSE ANOTHER SCHOLAR Drop Down Menu

Mario Chin, Ph.D.
ADARC Scholar

One of the hallmarks of HIV-1 is its high genetic variability, which is demonstrated by the large number of variants circulating in the human population. This property of HIV-1 enables the virus to escape antiviral drug and host immune pressures. Our research focuses on the evolution and adaption of HIV-1 in response to such selection pressures.

The first line of research aims to identify and characterizing cis-acting elements essential for RNA dimerization as novel antiviral targets. A number of antiviral drugs targeting different processes in the HIV replication cycle are available to control virus replication. Antivirals development has expanded to explore ways to hinder or prevent HIV-1 RNA dimerization because growing evidences have indicated that this process is essential for generating mature infectious viral particles. We seek to reveal new targets for blocking RNA dimerization that can affect the continuous replication of HIV-1 in the host. Both aminoglycoside-based and nucleic acids-based therapeutics have been used to target the major cis-acting element in the viral genome responsible for HIV-1 RNA dimerization. However, our study showed that HIV-1 without such element undergoes very rapid evolution by mutation or recombination with another strain, and regains wild type-like infectivity and pathogenicity in a very short period of time. The ever-changing nature of HIV-1 highlights the urgent need for finding more novel drug targets that prevent the replication of HIV-1. We are currently characterizing a series of cis-acting elements that affect the generation and dimerization of full-length HIV genomes. We study the adaptation of HIV-1 with mutations or deletions in these elements to delineate the escape pathways and assess the suitability of the element as antiviral target. Identifying and characterizing these cis-acting elements are important because it will provide knowledge needed to develop new strategies to curb HIV-1 replication.

A second line of research focuses on the generation and emergence of intersubtype recombinants in human. Genetic recombination is a major mechanism that generates rapid diversification of HIV-1 populations by reassorting mutations generated by reverse transcriptase. Recombination generates HIV-1 intersubtype recombinants and these recombinants now contribute significantly to the AIDS pandemic. We sought to test the hypothesis that the generation and emergence of HIV-1 intersubtype recombinant in the human population is selected by both the replication capacity of the virus and the CTL response of the host. Together with our collaborators at the Federal University of Sao Paulo, Brazil, we seek to define the correlation between disease progression rate and replication capacity of primary recombinant isolates or chimera carrying portion of the isolate in a neutral backbone. We study the function of the HIV-specific CTL response to elucidate the immune escape pathways of the recombinant and to reveal the dynamics of the duel between host and recombinant. Such information has important implications for HIV-1 vaccine development that aims at eliciting host CTL response.